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Abstract
Introduction: The mainstay of pharmacologic therapy for rheumatoid arthritis includes the use of disease-
modifying agents like sulfasalazine and methothrexate, and more recently, anti-tumor necrosis factor-a agents.
Depression remains a major co-morbidity in patients with rheumatoid arthritis and is thought to contribute to
disability and mortality in these patients. Evidence now suggests that a biologic link exists between substrates
responsible for inflammatory conditions and mood disorders. Most of this evidence comes from preclinical studies.
Nevertheless, more research into this area is helping us to understand the possible mechanisms through which
these conditions interact with each other.
Case presentation: We describe a 60-year-old Indian man with rheumatoid arthritis diagnosed 15 years ago who
had minimal response to multiple therapies with disease-modifying agents and whose arthritis symptoms
surprisingly remitted when he was started on a specific serotonin reuptake inhibitor antidepressant, three years
ago, for co-morbid major depression. This remission has been maintained with this medication, and the patient is
currently not taking any antirheumatoid medications.
Conclusion: Possible mechanisms linking substrates of mood disorders and inflammation are reviewed in this case
report, particularly the serotonergic system. Evidence seems to suggest a significant interaction between the
serotonergic systems and inflammation. This interaction seems to be bidirectional. An understanding of this
relation is most important to gain insight not only into pathophysiological mechanisms underlying this condition,
but also into how treatments for these conditions may complement each other and possibly provide greater
therapeutic options in both of these disabling conditions.
Introduction
Rheumatoid arthritis (RA) is a chronic, disabling condi-
tion that primarily affects joints, producing an inflam-
matory synovitis that often progresses to destruction of
the articular cartilage and ankylosis of the joints. Preva-
lence of RA is 1.16% in women and 0.44% in men in the
United Kingdom [1]. A similar prevalence has been
reported in India [2]. The mainstay of pharmacologic
therapy for RA includes the use of disease-modifying
agents (DMARDs) like sulfasalazine and methothrexate,
and more recently, “biologic agents” like anti-TNF-a
agents [3].
Conservative estimates suggest that major depressive
disorder affects between 13% and 17% of patients with
RA [4]. Major depressive disorder is thought to be an
independent risk factor for both work disability and
mortality in those with RA [5]. Clinical associations
between medical illnesses and major depressive disorder
are not solely attributable to illness-induced disability or
pain. A growing body of evidence implicates mechan-
isms involved in a bi-directional link between biologic
substrates of mood disorders and inflammation. Low-
dose tricyclic antidepressants (TCAs) have long been a
part of the armamentarium to treat pain and sleep dis-
turbance in this population. Few studies have reported
the effectiveness of specific serotonin reuptake inhibitors
(SSRIs) in this condition.
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remitted completely with an SSRI started for an episode
of major depressive disorder.
Case presentation
A 60-year-old Indian man (90 kg/170 cm) with a history
of RA, presented with features suggestive of a severe
depressive episode three years back. He had no previous
or family history of depression. He was first diagnosed
with RA fourteen years back and was treated with sulfa-
salazine and diclofenac for six years. He gradually devel-
oped resistance to these drugs, with persistent synovitis,
progressing joint deformities, and elevated erythrocyte
sedimentation rate (ESR) and C-reactive protein (CRP).
An acute exacerbation of the illness occurred six years
later, during which he was switched to a methotrexate
regimen thrice weekly, with partial response. He devel-
oped severe anemia and related angina with methotrex-
ate and had to discontinue methotrexate after three
years. Since the episode of angina, the patient was
started on a daily regimen of low-dose aspirin at 75 mg
and simvastatin at 40 mg. He continued to take various
non-steroidal anti-inflammatory drugs (NSAIDs) with-
out much effect until three years back, when he pre-
sented to his clinician with an episode of severe
depressive illness. He was referred to a psychiatrist, who
started him on escitalopram, a serotonin-specific reup-
take inhibitor, at 10 mg/day, and risperidone, an anti-
psychotic with a serotonin dopamine antagonist action
at 1 mg/day. Risperidone was started, as the patient
showed significant ruminative thoughts almost border-
ing on delusions. During this period, he was also taking
aspirin and simvastatin at the previously mentioned
doses.
Because the episode of depression was severe, it was
decided to maintain him on the antidepressant medica-
tion for at least a year after complete remission of his
depression. Before starting the patient on escitalopram
and risperidone, his DAS 28 score was 6.6, suggesting
that his arthritis was far from being under control. With
the combination of escitalopram and risperidone, along
with an improvement in his depressive symptoms, the
patient also perceived significant improvement in his
arthritis symptoms within a period of three to four
weeks. Risperidone was gradually tapered and stopped
after two months. His pain, morning stiffness, and fati-
gue continued to improve with escitalopram. Initially,
the perception of improvement in arthritis symptoms
was attributed to the improvement in his mood. How-
ever, his end-of-the-year rheumatology assessment
showed that his DAS 28 scores had significantly
improved to 2.2, being in the remission criteria range
suggested for the Indian population [6]. After a period
of one year taking escitalopram, it was decided gradually
to taper and stop his antidepressants. On stopping the
antidepressants, his joint pain and stiffness started to
worsen, and in two weeks, at the patient’sr e q u e s t ,h e
was recommenced on 10 mg of escitalopram and has
since been maintained on the same. His depressive ill-
ness and arthritis have been under remission since.
Discussion
SSRIs have been found to be effective in treatment of
depression in RA [7]. Recently Baune and Eyre [8]
reported a case of RA that responded to a combination
of SSRIs and antipsychotics. Our case differs from
Baune and Eyre’sr e p o r ti nt h a tt h ep a t i e n tw a st a k e n
off the risperidone (antipsychotic) in two months, but
continued to maintain his remission. More interesting is
that the patient continues to be under remission despite
not taking any disease-modifying agent or anti-inflam-
matory medications. The patient was taking the combi-
nation of aspirin, 75 mg, and simvastatin, 40 mg, for
almost five years before he was commenced on the psy-
chotropic medications. No perceived improvement in
arthritis was noted during this period. A clear temporal
association was found between the start of escitalopram
and the improvement in his arthritis. Further, his arthri-
tis relapsed when his escitalopram was stopped, and
improved when it was restarted. Therefore, the improve-
ment in the patient’s inflammatory condition could be
attributed to the psychotropic medication rather than to
the aspirin or the simvastatin.
A bi-directional relation seems to exist between biolo-
gic substrates of mood disorders and inflammation. For
example, inflammatory mediators like proinflammatory
cytokines are thought to have a direct impact on biolo-
gic substrates implicated in the pathophysiology of
mood, particularly the serotonergic system, and conver-
sely, serotonergic pathways are thought to be important
in mediating both inflammation and mood.
Inflammation modulates serotonergic system
Inflammation upregulates serotonin transporter
A key site of action of antidepressants is the serotonin
transporter (SERT), which regulates serotonergic neuro-
transmission. Data from preclinical studies indicate that
both the density and the activity of SERT are increased
by proinflammatory cytokines (for example, TNF-a),
leading to an increase in 5-HT uptake from the synapse,
thus decreasing 5-HT transmission [9]. This regulation
of neuronal SERT activity occurs via p38 mitogen-acti-
vated protein kinase-linked pathways. Data from our
group confirms this hypothesis in humans. Treatment
with TNF blockade agent adalimumab led to a decrease
in serotonin-transporter binding by up to 20% by using
[
123I]b-CIT-SPECT in a group of patients with rheuma-
toid arthritis [10].
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Some evidence suggests that proinflammatory cytokines,
including TNF-a, induce glial indoleamine 2,3-dioxygenase
(IDO). This activates the kynurenine pathway, thus chan-
neling the available tryptophan to form kynurenine (Kyn),
3-hydroxykynurenine (3HK), and quinolinic acid (QUIN),
rather than the serotonin (5-HT). This leads to a decrease
in the availability of 5-HT, thus contributing to the seroto-
nin-depletion hypothesis of depression. Further, 3HK and
QUIN are NMDA-receptor agonists. High concentrations
of these compounds lead to excitotoxicity and calcium-
mediated cell death. Taken together, some data support the
hypothesis that IDO pathway modulation plays a role in
the pathophysiology of cytokine-induced depression [11].
Anti-inflammatory agents have antidepressant properties
Muller et al. [12] showed that addition of celecoxib, a
COX-2 inhibitor that inhibits prostaglandin E2 to reboxe-
tine (a norepinephrine-reuptake inhibitor), showed signifi-
cant additional effects on depressive symptoms compared
with reboxetine alone. Specific TNF-blockade agents have
been shown to improve mood, independent of improve-
ment in the inflammatory condition. Tyring et al. [13]
found that 55% of patients with psoriasis who were treated
with etanercept showed a 50% reduction in their Beck
Depression Inventory (BDI) scores compared with 39% tak-
ing placebo, an effect size comparable to that of antidepres-
sants. Analyses of the individual items of the BDI showed
that significant improvements at week 12 were seen in feel-
ings of guilt, irritability, anhedonia, sleep, and sexual symp-
toms. All of them are deemed to be core depressive
symptoms. They also found that improvement in depres-
sion scores did not correlate with improvement in joint
pain, skin pain, or itching, suggesting that the improvement
in mood was independent of improvement in psoriasis.
Serotonergic systems modulate inflammation
Descending serotonergic pathways modulate inflammatory
pain
Descending spinal serotonergic pathways from the
medulla have long been implicated in the physiology of
pain modulation. Zhao et al. [14] showed that knockout
mice that lacked these descending serotonin pathways in
the brain showed normal thermal and visceral pain
responses but were less sensitive to mechanical stimuli
and exhibited enhanced inflammatory pain compared
with their littermate control mice. More specifically,
they showed that the analgesic effects of antidepressants
were absent in this strain of mice, suggesting that sero-
tonergic pathways play an important role in modulating
inflammatory pain, compared with mechanistic pain.
Antidepressants have anti-inflammatory and analgesic
properties
Antidepressants with a dual action (inhibiting serotonin
and norepinephrine reuptake) have been shown to have
analgesic properties and are recommended first-line
treatments in a number of painful conditions [15]. Tri-
cyclic antidepressants in low doses have been used regu-
larly in rheumatology clinics for their effect on pain,
mood, and sedation. Antidepressants also were shown
to induce an anti-inflammatory response, independent
of the antidepressant action. O’Brien et al. [16] showed
that C-reactive protein (CRP) levels decreased after
treatment with an antidepressant. This effect was inde-
pendent of its antidepressant effect. Vollmar et al. [17]
found that venlafaxine significantly decreased clinical
symptoms of disease in a murine autoimmune encepha-
lomyelitis model. They showed that venlafaxine sup-
pressed the generation of pro-inflammatory cytokines
IL-12 p40, TNF-a,a n dI F N - g in encephalitogenic T-cell
clones, splenocytes, and peritoneal macrophages in vitro.
Piletz et al. [18] found that increased pro-inflammatory
biomarkers in patients with major depressive disorder
showed a decrease in response to treatment with venla-
faxine (a mixed serotonin and norepinephrine-reuptake
inhibitor, exhibiting serotonin-reuptake inhibition at
lower doses, and norepinephrine-reuptake inhibition at
higher doses) at the serotonergic dose range rather than
at the norepinephrine dose range, suggesting that serto-
nergic pathways mediate the anti-inflammatory response
to anti-depressants. More recently, Sacre et al. [19]
found that fluoxetine and citalopram significantly inhib-
ited disease progression in murine collagen-induced
arthritis (CIA) models. Both drugs were also found to
inhibit significantly the spontaneous production of
tumor necrosis factor, IL-6, and IFN-g-inducible protein
10 in human RA synovial membrane cultures. The
potential mechanism through which fluoxetine and cita-
lopram treatment exhibited these anti-inflammatory
effects was explored. Both the drugs significantly inhib-
ited the signaling of Toll-like receptors 3, 7, 8, and 9,
providing a potential mechanism for their anti-inflam-
matory action. Toll-like receptors are proteins thought
to mediate innate immunity. They play an important
role in initiating an inflammatory reaction in response
to pathogen proteins and endogenous molecules found
at sites of inflammation and tissue damage.
5-HT2A receptors mediate the inflammatory response to
serotonin
Recent animal and human data suggest that certain sub-
types of serotonin receptors may play a role in mediat-
ing inflammatory processes. 5-HT2A receptors are
expressed widely throughout the central nervous system.
In the periphery, they are highly expressed in platelets
and many cell types of the cardiovascular system, in
fibroblasts, and in neurons of the peripheral nervous
system. Yu and colleagues [20] found that peripheral
activation of 5-HT2A receptors in primary aortic
smooth muscle cells leads to an extremely potent
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inflammation, a possible mechanism of action of SSRIs
in mediating the anti-inflammatory action. Interestingly,
they found that proinflammatory markers could also be
inhibited by 5-HT2A stimulation hours after treatment
with TNF-a (that is, after the onset of inflammation).
SSRIs, including escitalopram, are thought to increase
extracellular serotonin concentrations at these receptors.
However, SSRIs are thought to downregulate 5-HT2A in
the long run. Surprisingly, blockade of 5-HT2A receptors
(risperidone) also has the same effect (that is, downregula-
tion). This may seem paradoxical. Meyer et al. [21] sug-
gested that treatment with SSRIs led to a decrease in
5-HT2A binding potential, suggesting a decrease in recep-
tor density over a period of six weeks. They found that
this decrease in binding potential became less pronounced
with increasing age, suggesting that downregulation of
5-HT2A receptors decreased with age. This observation
was thought to be due to a possible floor effect caused
because the 5-HT2A-receptor density decreased with age.
Nevertheless, the 5-HT2A receptor downregulation sug-
gests that SSRIs do have an effect on 5-HT2A receptors.
The fact that this downregulation was less in older indivi-
duals in Meyer’s study means that the 5-HT2A stimulation
would continue without significant downregulation, possi-
bly leading to a powerful anti-inflammatory effect periph-
erally in these individuals, a possible reason that
escitalopram had this effect in the individual in the report.
Whether this downregulation is essential for the anti-
inflammatory effect must be investigated further.
In addition, it has been postulated that people taking
antidepressants that blocked 5-HT2A receptors are 45
times more likely to report an adverse drug reaction
pertaining to a joint, compared with those that did not
block these receptors, confirming the hypothesis that 5-
HT2A receptors play an important role in mediating
inflammatory processes [22].
Conclusion
In the present case, we see that treatment of co-morbid
depression with an SSRI led to complete remission of
arthritis in a 60-year-old individual. Postulated mechan-
isms through which antidepressants mediate this effect
include their agonistic action on 5-HT2A receptors or
inhibition of the signaling of Toll-like receptors that are
responsible for mediating innate immunity. The relation
between mediators of inflammation and biologic sub-
strates of mood seem to be bidirectional. Further studies
are required to elucidate the mechanisms involved in
this relation.
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